Table I.

Shared CNAs between STUMP (upper value) and sarcoma (bottom value).

Chr	Cytoband	AvgCGHLR	Gene names
1	p22.2-p22.1	3.37	TGFBR3
		3.39
2	q32.2	3.25	COL5A2
		2.95
12	q24.11	2.82	SART3, ISCU, TMEM119,
		2	SELPLG, CORO1C, SSH1
13	q32.1	2.51	UGCGL2
		1.51
19	q13.43	3.64	CHMP2A, UBE2M,
		1.98	LOC100131691, MZF1
21	q22.3	3.94	C2CD2, ZNF295
		2.02
22	q12.1	2.26	PITPNB
		2.21
X	q28	1.46	ARHGAP4, ARD1A,
		1.35	RENBP, HCFC1

TGFBR3: decreased expression of this receptor has been observed in various cancers (5–7). COL5A2: colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2 (20). SART3: an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy (www.genecards.org). CORO1C: silencing of CORO1C gene expression inhibited cancer cell proliferation, migration and invasion (10). SSH1: plays a role in cancer cell motility and invasion. Amplification reported in testicular germ cell tumor (21,22). CHMP2A: diseases associated include osteosarcoma, and adenocarcinoma (www.genecards.org). MZF1: significantly induces tumor formation and liver metastasis, furthermore, MZF1 expression is positively correlated with Axl expression in resected colorectal cancer. Diseases associated also include bladder TCC (www.genecards.org) (23).